Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia

NCT01452919 is registered in ClinicalTrials.gov with Denovo Biopharma LLC as lead sponsor.

NCT NCT01452919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01452919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia
Lead sponsor
Denovo Biopharma LLC
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
September 30, 2012
Enrollment
123 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia